{"id":3005,"date":"2024-12-15T20:50:00","date_gmt":"2024-12-15T19:50:00","guid":{"rendered":"https:\/\/transcience.fr\/projects-funded-by-the-european-union\/"},"modified":"2025-04-10T16:53:13","modified_gmt":"2025-04-10T14:53:13","slug":"projects-funded-by-the-european-union","status":"publish","type":"post","link":"https:\/\/transcience.fr\/en\/projects-funded-by-the-european-union\/","title":{"rendered":"Projects funded by the European Union"},"content":{"rendered":"\n

As part of the European Horizon 2020 program (the European Union’s research and innovation funding program for the years 2014 to 2020), 16 projects had focused on the development of animal-free, in vitro<\/em> or in silico<\/em> research, to the tune of 90 million euros.<\/p>\n\n\n\n

\u200b<\/p>\n\n\n\n

Among these projects, “EU Tox Risk<\/strong><\/a>“received a budget of 30 million euros for 6 years, involving 39 partners including Ineris for France, industrialists such as L’Or\u00e9al or Roche, universities, etc.<\/p>\n\n\n\n

It is described as “an integrated flagship program for the conduct of toxicity testing and risk assessment in the 21st century”. The vision is to “drive the paradigm shift in toxicological testing from the ‘black box’ of animal testing to toxicological assessment based on human cell responses and a full mechanistic understanding of the cause-effect relationships of harmful chemical effects.”<\/p>\n\n\n\n

This project covers the complex fields of toxicology: systemic repeated-dose toxicity (using the lungs, kidneys, liver and nervous system as examples of potential target organs) and developmental and reproductive toxicity, including endocrine disruptors.<\/p>\n\n\n\n

\u200b<\/p>\n\n\n\n

Another major project is “VAC2VAC<\/strong><\/a>“, collaborative research funded by the “Innovative Medicines Initiative” (IMI) that aims to develop and validate quality testing approaches for human and veterinary vaccines using non-animal methods. The initiative began on March 1, 2016.<\/p>\n\n\n\n

VAC2VAC is a public-private consortium of twenty partners, involving experts from the veterinary and human vaccine industry in partnership with official drug control laboratories, universities and translational research organizations. To achieve their goal, the partners must develop, optimize and evaluate physico-chemical and immunochemical methods, cell-based assays and others for routine testing of vaccine quality, safety and efficacy. This is done in collaboration with regulatory bodies. <\/p>\n\n\n\n

<\/div>\n\n\n\n

New projects started in 2021 under the Horizon Europe 2021-2027 program; 84 million allocated, including 60 million over 5 years awarded for 3 projects on the safety control of animal-free chemicals.<\/p>\n\n\n\n

<\/p>\n\n\n\n